Piramal Pharma Limited — Others, 20-02-2025: Copy of Newspaper Publication

Piramal Pharma Limited has announced a board meeting to review the financial results for the quarter and half-year. The meeting will allow for an assessment of performance, potentially leading to strategic adjustments. With plans being discussed, investors may see this as a positive outlook if results show improvement, but must remain cautious of any underlying risks affecting long-term growth. This meeting underscores the firm’s proactive approach in maintaining financial transparency and governance, which could foster investor confidence as they anticipate the outcomes.